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Fumonisins are mycotoxins produced by Fusarium
verticillioides. They are toxic to animals and exert their effects
through mechanisms involving disruption of sphingolipid metab-
olism. Fumonisins are converted to their hydrolyzed analogs by
alkaline cooking (nixtamalization). Both fumonisins and hydro-
lyzed fumonisins are found in nixtamalized foods such as tortillas,
and consumption of tortillas has been implicated as a risk factor
for neural tube defects (NTD). Fumonisin B1 (FB1) induced NTD
when given (ip) to pregnant LM/Bc mice; however, neither the
NTD induction potential of hydrolyzed fumonisin B1 (HFB1) nor
its affect on sphingolipid metabolism in pregnant mice have been
reported. The teratogenic potential of FB1 and HFB1 was therefore
compared using the LM/Bc mouse model. Dams were dosed (ip)
with 2.5, 5.0, 10, or 20 mg/kg (£ 49 mmol/kg) body weight (bw)
HFB1 on embryonic day (E)7–E8. Negative and positive control
groups were given vehicle or 10 mg/kg (14 mmol/kg) bw FB1,
respectively. The high dose of HFB1 disrupted sphingolipid
metabolism, albeit slightly, but did not cause maternal liver lesions
or NTD (n5 8–10 litters per group). In contrast, 10 mg/kg bw FB1
markedly disrupted maternal sphingolipid metabolism, caused
hepatic apoptosis in the dams, increased fetal death rates, and
decreased fetal weights. Furthermore, NTD were found in all FB1-
exposed litters (n5 10), and 66 ± 24% of the fetuses were affected.
The findings indicate that HFB1 does not cause NTD in the
sensitive LM/Bc mouse model and only weakly disrupts sphingo-
lipid metabolism at doses up to sevenfold higher (micromole per
kilogram body weight basis) than the previously reported lowest
observed adverse effect level for FB1.
Key Words: fumonisins; hydrolyzed fumonisin B1;
nixtamalization; reproductive toxicity; sphingolipids.
Fumonisins are mycotoxins produced by Fusarium
verticillioides (formerly Fusarium moniliforme Sheldon) and
Fusarium proliferatum (Gelderblom et al., 1991). They are
found worldwide in maize and maize-based foods (Bolger
et al., 2001 and references therein). Fumonisin B1 (FB1), the
most common congener, causes the animal diseases associated
with F. verticillioides exposure, including leukoencephaloma-
lacia in Equidae, pulmonary edema in swine, kidney and liver
toxicity in diverse species, and kidney and liver cancer in
rodents (Bolger et al., 2001; Gelderblom et al., 1991; Howard
et al., 2001; Voss et al., 2007b). The key molecular event
underlying toxicity is the inhibition of ceramide synthase
with subsequent disruption of sphingolipid metabolism and
sphingolipid-dependent physiological processes (Gelineau-van
Waes et al., 2009; Riley et al., 2001; Zitomer et al., 2009).
The human health effects of fumonisins are poorly
understood. Esophageal cancer rates have been correlated with
fumonisin concentrations in local maize (Bolger et al., 2001),
and Hendricks (1999) proposed that fumonisins were involved
in a cluster of neural tube defects (NTD) that affected babies
born to Mexican-American women living in the Texas counties
bordering Mexico in 1990–1991. Unusually high incidences of
equine leukoencephalomalacia and porcine pulmonary edema
were noted in the area during 1989, and residents consumed
locally grown maize harvested at that time. A correlation
between tortilla consumption (up to 400) during the first
trimester of pregnancy and increased risk of NTD was found
during a retrospective epidemiological study of the Texas
border region (Missmer et al., 2006). Risk was further increased
in women consuming homemade tortillas, presumably made
from locally grown maize, compared to those eating exclusively
commercial products. FB1 exposure during the critical gesta-
tional window for neural tube closure induces NTD in cultured
mouse embryos (Sadler et al., 2002) and in the more sensitive
LM/Bc (Gelineau-van Waes et al., 2005, 2009) and the less
sensitive CD1 (Voss et al., 2007a) mouse strains in vivo.
Nixtamalization is the alkaline cooking method for making
masa and tortillas from maize. Varying amounts of FB1 and
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other fumonisins are converted under alkaline conditions to
their hydrolyzed analogs (Fig. 1). Only a few surveys of
hydrolyzed fumonisins in nixtamalized products have been
reported. Amounts have been generally low (Dombrink-
Kurtzman and Dvorak, 1999; Dvorak et al., 2008; Park
et al., 2004; Seefelder et al., 2001); however, hydrolyzed
fumonisins occasionally constituted a high percentage of the
total fumonisins therein. When calculated on a micromolar
basis, hydrolyzed fumonisin B1 (HFB1) accounted for  50%
of the total FB1 analogs in masa (Dombrink-Kurtzman et al.,
2000; Voss et al., 2001) or tortillas (Dombrink-Kurtzman et al.,
2000; Palencia et al., 2003). Human exposure to HFB1 is
therefore likely, especially in areas where nixtamalized maize
is a diet staple (Missmer et al., 2006; Palencia et al., 2003).
HFB1 ( 100 lmol) induced anomalies, including NTD, in
cultured rat embryos (Flynn et al., 1997), suggesting that it,
like FB1, might induce anomalies in vivo when tested in
a sensitive animal model. HFB1 is metabolized in vivo by rats
to N-acylated metabolites that are structural analogs of
ceramide (Seiferlein et al., 2007) and were more cytotoxic
than HFB1 in vitro (Abou-Karam et al., 2004; Seiferlein et al.,
2007). The objectives of this study were to compare the NTD
induction potential of HFB1 and FB1 and their ability to disrupt
sphingolipid biosynthesis using the sensitive LM/Bc mouse
model (Gelineau-van Waes et al., 2005). HFB1 did not induce
NTD at a dose level that was significantly higher than the
reported lowest observed adverse effect level for NTD
induction by FB1 (Gelineau-van Waes et al., 2005). HFB1
disrupted maternal sphingolipid metabolism, although much
less potently than FB1. Together, the findings indicate that,
compared to FB1, HFB1 is not a significant risk factor for NTD.
MATERIALS AND METHODS
FB1 and HFB1. FB1 was provided by Dr Robert Eppley, Center for Food
Safety and Nutrition, U.S. Food and Drug Administration, College Park, MD.
HFB1 was prepared by hydrolysis of FB1 in 2 N KOH (70C overnight). After
hydrolysis, the HFB1 was cleaned up over a 35 cc C18 SepPak column (Waters,
Milford, MA) (Voss et al., 1996) that was eluted in sequence with 30% aqueous
acetonitrile, 70% acetonitrile, and actonitrile. The eluants were assayed by
high-performance liquid chromatography (HPLC)-fluorescence detection after
precolumn derivatization with ortho-phthalaldehyde (OPA) (Pierce, Rockford,
IL) (Burns et al., 2008) to confirm elution of HFB1 only in the 70% fraction.
After removal of the solvent from the 70% fraction by rotoevaporation and
freeze drying, the purity of the HFB1 preparation (a slightly yellow oily
material) was assessed by liquid chromatography-tandem electrospray
ionization mass spectrometry as described in Zitomer et al. (2008).
Dosing solutions. The high-dose solution (2 mg/ml) was prepared by
dissolving the HFB1 preparation in 50 ml hypotonic (0.3%) saline, which also
served as the dosing vehicle. HFB1 concentration of the high-dose solution was
determined by HPLC as described above (Burns et al., 2008), with
quantification by comparison to an external standard of HFB1 (generously
provided by M. Busman, United States Department of Agriculture (USDA),
Agricultural Research Service (ARS), Peoria, IL). The remaining dosing
solutions (0.25, 0.5, and 1 mg/ml) were prepared by diluting aliquots of the
high-dose solution with vehicle. The dosing solutions were sterile filtered
(Millex-GV 0.22 lm filters; Millipore, Bedford, MA) into autoclaved bottles
affixed with rubber caps and stored refrigerated. The dosing solution for the
positive control group, 1 mg/ml FB1 (determined gravimetrically), was
prepared in the same manner.
Animals. The experimental protocol was approved by Institutional Animal
Care and Use Committee, Richard B. Russell Agricultural Research Center,
USDA, ARS. Acclimated male and female mice of the inbred LM/Bc strain
(Gelineau-van Waes et al., 2005) were individually housed (except during
mating) in stainless steel wire-mesh cages kept in an environmentally
controlled room with a 12-h light/dark cycle. The animals had free access to
feed (2019 Global Diet; Tecklad, Madison, WI) and fresh tap water.
Experimental design. Mating pairs were randomly selected and cohabited
in the males’ cages. Females were examined each morning, and the first day in
which a vaginal plug was observed was designated embryonic day (E)0. On E0,
the females were weighed and assigned to one of six groups by stratified
randomization. They were observed daily and weighed again on E6, E9, E15,
and before necropsy.
The dams were dosed in the mornings of E7 and E8 with 0 (vehicle control),
2.5, 5.0, 10, or 20 mg/kg body weight (bw) HFB1 administered by ip injection
at a volume rate of 10 ml/kg bw. The positive control group was treated with 10
mg/kg bw FB1 as described. One half of the females were euthanized (CO2) on
E9 and the remainder on E16. At necropsy, the internal organs were examined
and the maternal liver and kidneys weighed. Implantation sites were counted on
E9. Gravid uteri were weighed on E16 and their contents examined (see below).
Specimens of maternal liver were fixed in 10% neutral-buffered formalin at
both E9 and E16. Additional liver samples were frozen (80C) for
sphingolipid analyses.
Uteri from dams killed on E16 were excised and examined to determine the
number of total implantation sites, early resorptions, late fetal deaths, and viable
fetuses. Fetuses were excised, examined for NTD, and weighed. The livers and
placenta from two fetuses per litter were collected, weighed, and stored frozen
(80C) for biochemical evaluations.
Histopathology. The livers of five dams killed at E9 and five killed at E16
from the vehicle control, high-dose HFB1 (20 mg/kg bw), and positive control
(10 mg/kg bw FB1) groups were processed, stained with hematoxylin and
eosin, and microscopically examined.
Sphingolipid analysis. Free sphingoid bases and sphingoid base
1-phosphates were quantified by liquid chromatography-mass spectrometry
FIG. 1. The chemical structures of FB1 and its full hydrolysis product.
Under alkaline conditions, including those found during cooking by
nixtamalization, FB1 is converted to HFB1 by hydrolytic cleavage of the
carballylic acid (propane 1-2-3 tricarboxylic acid) groups (arrows) attached to
the FB1 hydrocarbon ‘‘backbone’’ at the C14 and C15 positions.
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(LC-MS) as described by Zitomer et al. (2009). Complex sphingolipids (CSL)
were extracted and acid hydrolyzed as described in Riley et al. (2000) and the
sphingoid base backbones quantified by LC-MS (Zitomer et al., 2009).
Free sphinganine (Sa) concentrations in maternal liver were quantified for
five dams per group killed on E9. More detailed sphingolipid profiles were
determined at E9 and E16 for randomly selected females from the vehicle
control, high-dose HFB1, and the positive control groups. The more extensive
profiles included the concentrations of free Sa, sphingosine (So), sphingoid
base 1-phosphates (Sa 1-P and So 1-P), 1-deoxy sphinganine (1-deoxy Sa) as
well as CSL in maternal liver (n ¼ 5 per group), fetal liver (n ¼ 4–5 per group),
and placentae (n ¼ 5 per group) from the vehicle control, 20 mg/kg bw HFB1,
and 10 mg/kg bw FB1 groups. The concentration of a novel compound
tentatively identified as 1-deoxy sphingosine (1-deoxy So) (see ‘‘Discussion’’
section) was also estimated.
Statistics. Statistical analyses were done using Sigma Stat (Systat
Software, San Jose, CA). Parametric data were analyzed by one-way ANOVA
followed by Duncan’s test to identify differences among groups. Non-
parametric data were analyzed using the Kruskal-Wallis rank sum test followed
by Tukey’s test or, for sphingolipid profile results, by ANOVA after log10
transformation (Riley and Voss, 2006). Tests were two tailed, and significance
was judged at p < 0.05.
RESULTS
HFB1 Preparation
No FB1 was detected in any of the cleanup fractions. HFB1
eluted exclusively in 70% acetonitrile, and the HPLC chromato-
gram of this fraction did not reveal any other significant OPA-
positive peaks (data not shown). LC-MS (total ion chromato-
gram, scan range ¼ 100–2000 m/z, Fig. 2A) of this fraction
revealed a single peak having the same retention time and m/z
(406) as standard HFB1. The material exhibited the same mass
spectra as the HFB1 standard when evaluated by mass
spectrometry/mass spectrometry (Fig. 2B).
Maternal Clinical, Necropsy, and Histopathology
Neither HFB1 nor FB1 had any effect on the general
appearance of the animals. No differences in maternal body
weight between the vehicle control and other groups were
found, although the weight of the dams given 10 mg/kg bw
FB1 (35.3 ± 2.6 [SD] g) was 8–12% lower than that of the other
groups (38.4 ± 3.9 to 39.9 ± 1.6 g) on E15. Weight gains, E6
through E15, of the groups given HFB1 ranged from 6.7 ± 2.8
(10 mg/kg bw) to 7.9 ± 2.2 g (20 mg/kg bw) and did not differ
from the vehicle controls. Weight gain of the positive control
group (4.0 ± 2.0 g) during gestation was significantly decreased
compared to all groups (7.2 ± 1.1 to 7.9 ± 2.2) except the one
given 10 mg/kg bw HFB1 (6.7 ± 2.8).
Except for an increase in relative liver weight of the dams
given 10 mg/kg bw FB1 (6.7 ± 0.68% bw compared to 5.7 ±
2.1% bw in the vehicle controls), no differences in absolute
or relative organ weights were found at E16. This difference
reflected the slightly lower (~8–12% lower than other groups,
not significantly different) body weight of the FB1-treated
dams.
No liver lesions attributable to HFB1 were found at either E9
or E16. In contrast, 10 mg/kg bw FB1 caused overt hepatic
lesions in all dams examined on E9 that were consistent with
FIG. 2. Mass spectrometric confirmation of the total conversion of FB1 to HFB1. (A) Total ion chromatogram showing a single peak corresponding to HFB1
(m/z ¼ 406) in the preparation used to make the dosing solutions. No FB1 (m/z ¼ 722) was found therein. (B) Chromatogram of the single peak at m/z ¼ 406
obtained by mass spectrometry/mass spectrometry showed the same fragmentation pattern as standard HFB1. y-axes indicate relative abundance.
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the effects of FB1 (Bolger et al., 2001; Gelineau-van Waes
et al., 2009; Voss et al., 2007b) and judged to be moderately
severe. Specific features included scattered hepatocellular
apoptosis, less frequently observed foci of necrosis involving
single to a few hepatocytes, increased numbers of mitotic
figures, and variability in cell and nucleus size. The hepatic
lesions were readily reversible. The only evidence suggestive
of FB1 exposure remaining at E16 was a minimal number of
isolated small foci of necrotic cells and, subjectively, slightly
more mitotic figures than seen in the other groups.
Reproductive Data
No differences in the number of total implants/dam were
found at E9 or E16. Counts ranged from 9.0 (5.0 mg/kg bw
HFB1) to 12.4 (20 mg/kg bw HFB1) at E9 (data not shown) and
from 9.9 (10 mg/kg bw HFB1) to 11.8 (2.5 mg/kg bw HFB1) at
E16 (Table 1). No statistically significant differences were
found among the vehicle control and HFB1-treated groups at
E16 for the following (Table 1): early resorptions/litter, late
deaths/litter, or live fetuses/litter. HFB1 also had no significant
effect on (live) fetal or placental weight. In contrast, 10 mg/kg
bw FB1 was fetotoxic (Table 1) as demonstrated by the
significant decrease in viable fetuses (group mean ¼ 3.9
compared to 8.6–10.0 in the other groups) and increase in late
fetal deaths (group mean ¼ 3.0 compared to 0.3–0.7 in the
other groups) found in the positive control litters. The number
of early resorptions/positive control litter (mean ¼ 4.6) was
also higher than in the other groups (means ranged from 0.5 to
1.7), although a statistical difference from the vehicle control
group was not demonstrated. Fetal and placental weights of the
positive control group were also significantly decreased: their
respective values were 40 and 26% less than those of the
vehicle control group (Table 1).
No fetuses with NTD were found in the vehicle control or
any HFB1-treated group. At least one NTD-affected fetus was
found in all litters from dams treated with 10 mg/kg bw FB1,
and in all cases, the anomaly presented as exencephaly. NTD
were found not only in apparently viable fetuses but were also
recognizable in some of the dead fetuses that had not yet
undergone advanced autolysis. As a result, the number of
NTD/positive control litter (mean ¼ 4.7) was higher than that
of viable fetuses/litter (mean ¼ 3.9).
Tissue Sphingolipids
Multiple changes in the tissue sphingolipid profiles were
found in the high-dose (20 mg/kg bw) HFB1 group and, to
a significantly greater extent, in the positive control (10 mg/kg
bw) FB1-treated group. Most effects were reversible, that is,
with a few exceptions, the differences between the HFB1- or
FB1-treated and vehicle control groups were more pronounced
1 day after the last dose (E9) than a week later (E16).
Dams
A dose-dependent increase in Sa (picomole per gram) of
maternal liver was found in the HFB1-treated groups on E9
(Fig. 3), and as a result, Sa in the high-dose group was
significantly greater than in the vehicle control group. Liver Sa
of dams treated with FB1 (10 mg/kg bw) was markedly
(Table 2) elevated and significantly increased compared to all
other groups, including the high-dose HFB1 group. Concen-
trations of 1-deoxy Sa were slightly higher (1.9-fold) in the
high-dose HFB1 group than in the vehicle controls on E9 and
markedly increased in the FB1-treated dams at that time.
Concentrations of both Sa and 1-deoxy Sa in the high-dose
HFB1-treated and FB1-treated groups decreased sharply after
TABLE 1
Reproductive and Litter Data of Dams Given 0–20 mg/kg bw HFB1 or 10 mg/kg bw FB1 by ip Injection on E7 and E8
a
Treatment
Total
implants
Early
resorptions
Late fetal
deaths
Viable
fetuses
Postimplant
death index
Weights
Litters
with NTDdFetusesb (g) Placentaec (mg)
HFB1 mg/kg bw
0 (vehicle control) (n ¼ 8 litters) 11.2 (1.0) 1.1e,f (1.0) 0.3e (0.5) 9.9e (1.6) 12.2e (11.6) 0.55e (0.05) 124.3e (10.2) 0e
2.5 (n ¼ 8 litters) 11.8 (2.1) 1.3e,f (1.3) 0.5e (0.5) 10.0e (2.0) 14.5e (11.2) 0.54e (0.06) 112.9e,f (12.1) 0e
5.0 (n ¼ 8 litters) 11.0 (1.9) 0.5e (0.8) 0.5e (0.8) 10.0e (1.1) 7.9e (9.4) 0.47e (0.09) 118.5e,f (17.2) 0e
10 (n ¼ 9 litters) 9.9 (3.9) 0.9e,f (1.1) 0.4e (0.7) 8.6e,f (3.6) 12.6e (12.4) 0.54e (0.12) 123.7e (15.0) 0e
20 (n ¼ 9 litters) 11.0 (1.9) 1.7e,f (2.0) 0.7e (1.0) 8.7e,f (3.5) 23.8e,f (25.5) 0.53e (0.07) 122.4e (15.9) 0e
FB1 mg/kg bw
10 (positive control) (n ¼ 10 litters) 11.5 (2.1) 4.6f (3.0) 3.0f (0.9) 3.9f (2.1) 66.2f (18.4) 0.33f (0.07) 92.4f (14.1) 10f [4.7]
Note. Values in columns not sharing superscript (e,f) are significantly different, p < 0.05.
aE0 is defined as the day on which a vaginal plug was first observed; dams were euthanized and litters examined on E16, 1 week after the last dose.
bValue is the average of the mean (SD) fetus weights for each litter.
cValue is the average mean (SD) of two randomly selected placentae/litter.
dValue indicates the number of litters having at least one NTD-positive fetus; number in brackets indicates the average number of affected fetuses/litter.
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E9 and, with the exception of 1-deoxy Sa in positive control
dams, no significant differences were found at E16 (Table 2).
Concentrations of Sa 1-P were increased (63-fold relative to the
vehicle controls) on E9 only in the FB1-treated positive
controls (Table 2). Thereafter, Sa 1-P concentrations in this
group decreased so that the difference (significant at p < 0.05)
between this group and the vehicle controls was 2.7-fold by
E16. Sa 1-P was also significantly elevated (about threefold) in
the high-dose HFB1-treated group but only at E16.
On E9, So concentration was slightly elevated in both the
high-dose HFB1-treated and the FB1-treated groups, although
statistical significance was demonstrated only for the latter. No
differences in So concentration were found at E16 and no
differences in So 1-P levels were found at either time.
Concentrations of the putative 1-deoxy So were significantly
elevated at E9 in the high-dose HFB1-treated group and to
a significantly greater extent in the positive control group.
Amounts in the vehicle control group at E9 and E16, as well as
in the high-dose HFB1 and positive control groups at E16, were
negligible
The treatments also affected maternal CSL, although the
pattern of response found in the HFB1- and FB1-exposed
groups differed (Table 3). FB1 treatment significantly decreased
all four classes of CSL examined at E9. Like other sphingolipid
changes, the effect was reversible: no significant differences
were found between the vehicle and positive control groups on
E16. In contrast, in dams treated with 20 mg/kg bw HFB1, CSL
incorporating So or 1-deoxy Sa were not decreased and CSL
incorporating Sa as well as those incorporating 1-deoxy So
were significantly increased on E9. Concentrations of the latter
two CSL classes decreased after E9 so that there were no
significant differences at E16.
Placentae
Placentae were only collected for analysis on E16. While no
differences between the 20 mg/kg bw HFB1-treated and the
vehicle control groups were found (data not shown), there were
several differences between the positive control and the other
two groups. These included the following: increased Sa (9.2 ±
2.3 nmol/g compared to a range of 6.0 ± 1.1 to 6.2 ± 1.0 nmol/g
in the other groups), increased 1-deoxy Sa (9.0 ± 2.9 nmol/g
compared to 1.4 ± 0.2 to 2.5 ± 1.9 nmol/g in the other groups),
and increased 1-deoxy So (8.7 ± 5.1 nmol/g compared to
TABLE 2
Liver Concentrations of Selected Sphingoid Bases and Their Metabolites in Pregnant LM/Bc Mice 1 Day (E9) and 8 Days (E16) after
Treatment with 0 (Vehicle Control Group) or 20 mg/kg bw HFB1 or 10 mg/kg bw FB1 (Positive Control Group) on E7 and E8
a
Day and treatment
Free sphingoid bases and metabolites (pmol/g)b
Sa 1-deoxy Sa Sa 1-P So 1-deoxy Soc So 1-P
E9
Vehicle 1330d (210) 287d (72) 8d (1) 2406d (466) ND 127 (37)
HFB1 20 mg/kg bw 2501
e (683) 509e (135) 12d (5) 5834d,e (4621) 28d (8) 150 (33)
FB1 10 mg/kg bw 73,388
f (16811) 4105f (649) 504e (85) 7616e (1102) 246e (57) 162 (53)
E16
Vehicle 1843 (181) 214d (31) 10d (5) 2203 (778) ND 92 (20)
HFB1 20 mg/kg bw 1482 (197) 197
d (23) 32e (14) 1882 (192) ND 124 (33)
FB1 10 mg/kg bw 3487 (1116) 343
e (77) 27e (8) 2831 (778) ND 99 (25)
Note. 1-Deoxy-Sa, 1-deoxysphinganine; 1-Deoxy So, 1-deoxy sphingosine (putative); ND, not detected; Sa 1-P, sphinganine 1-phosphate; So 1-P, sphingosine
1-phosphate.
Values in columns at each time (E9 or E16) not sharing superscript (d,e,f) are significantly different, p < 0.05.
aThe first day in which mating was confirmed by the presence of a vaginal plug is defined as E0.
bValues are the group mean; the SD is given in parentheses, n ¼ 4–5 per group.
cDue to unavailability of a standard, provisional identification of this compound as 1-deoxy So is based on mass spectral properties and tissue concentration data
(see text).
FIG. 3. Concentrations of sphinganine (Sa) in maternal liver were increased
in a dose-dependent manner on E9. The dams were given up to 20 mg/kg bw
HFB1 on E7 and E8 by ip injection and euthanized 24 h later for hepatic
sphingolipid analysis. Liver sphinganine concentrations of dams given FB1 by the
same protocol were significantly higher than those given the high dose of HFB1
(Table 2). Values indicate the group mean; error bars denote SD; n¼ 5 per group.
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1.3 ± 0.4 to 2.7 ± 1.7 nmol/g in the other groups). The 1-
phosphate metabolites of Sa and So were both decreased in the
placentae of dams given 10 mg/kg FB1: the respective results
for Sa 1-P and So 1-P were 64 ± 13 and 238 ± 61 pmol/g. Sa 1-
P averaged 108 ± 19 to 121 ± 42 and So 1-P averaged 304 ± 58
to 352 ± 69 pmol/g in the vehicle control and HFB1-treated
groups, respectively. No statistically significant differences in
placental CSL were found. However, CSL incorporating Sa or
So in the 20 mg/kg bw HFB1 and 10 mg/kg bw FB1 groups
averaged 20–30% less than their corresponding vehicle control
values. Conversely, CSL incorporating the compound tenta-
tively identified as 1-deoxy So averaged 27 and 65% higher in
the groups treated with 20 mg/kg bw HFB1 or 10 mg/kg bw
FB1, respectively. A similar pattern was apparent for CSL
incorporating Sa.
Fetal Liver
There was a slight increase in 1-deoxy Sa and a slight decrease
in So 1-P in fetal livers of the positive control group at E16 (data
not shown). No other significant differences in free sphingoid
base or complex sphingolipid concentrations were found.
DISCUSSION
The etiology of NTD is complex and involves genetic,
environmental, and nutritional components (Gelineau-van
Waes et al., 2009; Green and Copp, 2005). Epidemiological
(Missmer et al., 2006) and experimental (Gelineau-van Waes
et al., 2005, 2009) evidence suggest that fumonisins are
a potential NTD risk factor in populations dependent upon
maize as a diet staple. Consumption of tortillas, especially
homemade tortillas likely containing fumonisins, during the
first trimester of pregnancy was identified as an NTD risk
factor (Missmer et al., 2006).
Tortillas are made from masa produced by the alkaline
cooking process known as nixtamalization. The process differs
somewhat among households and commercial operations so
that, depending on cooking conditions, recipe, and quality of
the maize, the amount of fumonisins remaining in the masa is
variable (De La Campa et al., 2004). Surveys for hydrolyzed
fumonisins in nixtamalized products are limited but suggest
that, while concentrations are generally low, their contribution
to total fumonisin content can be significant. HFB1 constituted
25% (micromolar basis) of the FB1 analogs in masa, made from
low-quality maize (Voss et al., 2001). Equimolar amounts of
HFB1 and FB1 were found in tortillas made using the process
as practiced in Guatemalan households (Palencia et al., 2003)
and the micromolar ratio of HFB1:FB1 in a survey of
nixtamalized products from Sonora, Mexico, averaged from
0.37 to 0.62 (Cortez-Rocha et al., 2005). HFB1:FB1 ratios in
alkaline-cooked snacks from the German market ranged from
0.2 to 3.7 (Seefelder et al., 2001). Dvorak et al. (2008) found
HFB1 in 22 of 38 tortilla samples and micromolar ratios of
HFB1:FB1  0.5 were found in 22% of the positive samples.
Ratios from 0.94 to 1.48 were found in masa, tortillas, and
tortilla chips prepared in the laboratory from contaminated corn
(Dombrink-Kurtzman et al., 2000). Together, these surveys
indicate that pregnant women, especially those consuming
large amounts of alkaline-cooked maize, are exposed at least on
occasion to HFB1.
The LM/Bc mouse was selected as the test strain because,
using the ip dosing protocol of Gelineau-van Waes et al. (2005,
2009), it is the most sensitive animal model for NTD induction
TABLE 3
Liver Concentrations of Selected Complex Sphingolipids in Pregnant LM/Bc Mice 1 Day (E9) and 8 Days (E16) after Treatment with
0 (Vehicle Control Group) or 20 mg/kg bw HFB1 or 10 mg/kg bw FB1 (Positive Control Group) on E7 and E8
a
Day and treatment
Complex sphingolipid (pmol/g)b
CSL-Sa CSL-1-deoxy Sa CSL-So CSL-1-deoxy Soc
E9
Vehicle 4974d (665) 999e (262) 115,665e (21,361) 216e (37)
HFB1 20 mg/kg bw 7744
e (558) 1209e (140) 135,692e (24,336) 330d (49)
FB1 10 mg/kg bw 535
f (776) 149d (221) 20,136d (8184) 39f (59)
E16
Vehicle 3985 (783) 1071 (344) 137,003 (28,071) 165d,e (37)
HFB1 20 mg/kg bw 3830 (246) 1030 (465) 132,380 (34,397) 136
d (39)
FB1 10 mg/kg bw 4966 (706) 1200 (516) 157,136 (50,528) 235
e (57)
Note. CSL-1-deoxy Sa, complex sphingolipids incorporating 1-deoxy sphinganine; CSL-1-deoxy So, complex sphingolipids incorporating (putative) 1-deoxy
sphingosine; CSL-Sa, complex sphingolipids incorporating sphinganine; CSL-So, complex sphingolipids incorporating sphingosine; ND, not detected.
Values in columns at each time (E9 or E16) not sharing superscript (d,e,f) are significantly different, p < 0.05.
aThe first day in which mating was confirmed by the presence of a vaginal plug is defined as E0.
bValues are the group mean; the SD is given in parentheses, n ¼ 4–5 per group.
cDue to unavailability of a standard, provisional identification of the sphingoid base 1-deoxy So is based on mass spectral properties and tissue concentration
data (see text).
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by FB1. While the no observed adverse effect level in this model
has not been rigorously established, the experiments of
Gelineau-van Waes et al. (2005) suggest that it is below 5
mg/kg bw. At the latter dose, they found that 40% of the litters
(at least one fetus with NTD found in the litter) and 5% of the
total fetuses were NTD positive. Both variables increased in
a dose-related manner so that 100% of the litters were affected
at  15 mg/kg bw and the maximum incidence of affected
fetuses, about 80%, was found at the highest dose tested,
20 mg/kg bw FB1. In this experiment, HFB1 was clearly less
potent than FB1 as it did not elicit NTD when given at 20 mg/kg
bw, a dose that equals 49 lmol/kg bw. This is 3.5-fold higher
than the positive control dose of FB1 (10 mg/kg bw ¼ 14 lmol/
kg bw) and sevenfold higher than 5 mg/kg bw FB1 (7 lmol/kg
bw), the lowest dose tested by Gelineau-van Waes et al. (2005).
A lowest adverse affect level for HFB1-induced fetotoxicity
was not established and some data suggest that overt
fetotoxicity would appear at higher doses. First, late deaths
were twice as frequent in high dose as in the vehicle control
litters. The number of live fetuses/litter at 10 or 20 mg/kg bw
tended to be lower than in the other HFB1-treated and vehicle
control groups. While not significantly different from those
groups, the late fetal death rate in the high-dose group was also
not significantly different from the positive control group.
Accordingly, the postimplant death index of the high-dose
group was twice that of the vehicle controls and was not
significantly different from the positive control group.
FB1 was moderately hepatotoxic to the dams at E9. As
previously observed in rats (Voss et al., 1998), hepatotoxicity
was reversible as 1 week later, at E16, only a few isolated
apoptotic, necrotic, or mitotic cells were present. HFB1 was in
contrast not hepatotoxic as judged by morphological criteria,
a finding that is in agreement with Howard et al. (2002), who
found microscopic lesions in female mice fed  50 ppm FB1
for 4 weeks, but not in groups fed micromolar equivalents of
HFB1. Similarly, oral doses of 120 mg/kg bw HFB1 were not
toxic to pregnant rats (Collins et al., 2006), whereas in
a separate study,  25 mg/kg FB1 bw caused significant
nephrotoxicity and heptotoxicity (Collins et al., 1998).
Fumonisins disrupt sphingolipid metabolism by inhibiting
ceramide synthases, enzymes catalyzing the de novo synthesis
of ceramide from fatty acids and sphingoid bases (Riley et al.,
2001; Zitomer et al., 2009). The ensuing disruption of
sphingolipid-dependent signaling and physiological processes
is the key event mediating fumonisin’s diverse biological
effects (Bolger et al., 2001; Gelineau-van Waes et al., 2009;
Riley et al., 2001; Voss et al., 2007b), which include inhibition
of folate utilization (see below) (Gelineau-van Waes et al.,
2005; Sadler et al., 2002; Stevens and Tang, 1997). HFB1
disrupts ceramide synthase in vitro 3–10 times less potently
than FB1 (Norred et al., 1997; Seefelder et al., 2002).
Nixtamalized Fusarium culture materials increased kidney
and liver Sa and So concentrations when fed to rats (Burns
et al., 2008; Voss et al., 1998), although the possibility remains
that these effects were mediated by residual or ‘‘hidden’’ FB1
(matrix-bound forms not detected by HPLC) (Kim et al., 2003;
Park et al., 2004) remaining in the nixtamalized preparations
rather than HFB1. In this regard, it is noteworthy that liver Sa
of female mice fed diets amended with 143 lmol/kg HFB1
(150 ppm FB1 equivalents) was unaffected (Howard et al.,
2002).
The results of this experiment are to our knowledge the first
unequivocal demonstration of sphingolipid metabolism disrup-
tion in vivo by HFB1. HFB1 is acylated by ceramide synthase in
vitro and by rats in vivo (Seiferlein et al., 2007). The
N-acylated metabolites are structural analogs of ceramide,
inhibited ceramide synthase, and were more potent cytotoxins
than HFB1 when tested in HT29 human colorectal (Seiferlein
et al., 2007) or other mammalian cell lines (Abou-Karam et al.,
2004). Studies are needed to determine if the metabolic effects
in the HFB1-treated mice were mediated directly by HFB1,
indirectly by N-acyl metabolites, or both. Regardless, HFB1
was a significantly less potent modulator of sphingolipid
metabolism than FB1.
The identity of a novel metabolite previously observed to
accumulate in cells exposed to FB1 has been recently identified
as the novel sphingoid base, 1-deoxy Sa that, like Sa, was
cytotoxic to LLC-PK1 and DU-145 cells (Zitomer et al., 2009).
The increase, albeit transient, of 1-deoxy Sa in liver of the
dams dosed with 10 mg/kg bw FB1 or 20 mg/kg bw HFB1 in
this study independently confirms that it accumulates in the
liver of fumonisin-exposed mice as reported by Zitomer et al.
(2009). Liver concentration of another compound tentatively
identified as 1-deoxy So was also transiently elevated by both
fumonisins. Structural confirmation was not possible as
a standard is currently unavailable. Identification as 1-deoxy
So was inferred from the mass ion (m/z ¼ 284.2) and the
similarity of the compound’s mass spectra to that of 1-deoxy
Sa. The concurrent elevation of putative 1-deoxy So and
depletion of its CSL by FB1 inhibition of ceramide synthase is
further evidence that the compound is a sphingoid base.
Structural confirmation and in vivo toxicological significance of
the putative 1-deoxy So remains to be determined.
There is evidence both against and for fumonisins being
NTD risk factors. FB1 was not teratogenic to rabbits (LaBorde
et al., 1997), rats (Collins et al., 1998), or CD1 mice (Reddy
et al., 1996) when given orally at maternally toxic doses.
However, folate deficiency increases NTD risk (Green and
Copp, 2005; reviewed by Gelineau-van Waes et al., 2009;
Missmer et al., 2006) and FB1 inhibited 5-tetramethylfolate
uptake by CaCo2 cells through a mechanism involving
complex sphingolipid depletion (Stevens and Tang, 1997).
Accordingly, folate supplementation partially protected cul-
tured mouse embryos from NTD induction by FB1 (Sadler
et al., 2002), while both folate and, more effectively, the
complex sphingolipid GM1 protected LM/Bc mouse embryos
in utero (Gelineau-van Waes et al., 2005). Our results are in
conformity with the latter findings insofar as CSL were
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depleted only on E9 and only by the treatment (20 mg/kg bw
FB1) eliciting NTD. It can be supposed that a threshold for
NTD induction by fumonisins, perhaps including hydrolyzed
fumonisins, would be lower in animals that have a preexisting
vulnerability because of nutritional deficiencies, environmental
conditions, or genetic predisposition (Gelineau-van Waes et al.,
2009). Other consequences of ceramide synthase inhibition
potentially contributing to NTD induction should also be
considered. These include imbalances in pro-apoptotic (Sa) and
‘‘pro-survival’’ (So 1-phosphate) metabolites, inappropriate
intercellular or intracellular signal transduction by So (or Sa)
1-phosphates or cytokines, as well as nonspecific events such
as oxidative damage (Bolger et al., 2001; Gelineau-van Waes
et al., 2009).
In summary, HFB1 did not induce NTD when tested using
the sensitive LM/Bc mouse model at 20 mg/kg bw, a dose
which disrupted sphingolipid metabolism, albeit slightly. At
the lesser dose level of 10 mg/kg bw, FB1 markedly disrupted
sphingolipid metabolism, caused moderate apoptotic liver
lesions, and induced NTD. The results provide further evidence
that hydrolyzed fumonisins are less toxic in vivo than their
corresponding parent fumonisins and, specifically, that they are
not a significant risk factor for NTD.
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